Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

PubWeight™: 35.24‹?› | Rank: Top 0.01% | All-Time Top 10000

🔗 View Article (PMC 3563263)

Published in N Engl J Med on June 02, 2012

Authors

Julie R Brahmer1, Scott S Tykodi, Laura Q M Chow, Wen-Jen Hwu, Suzanne L Topalian, Patrick Hwu, Charles G Drake, Luis H Camacho, John Kauh, Kunle Odunsi, Henry C Pitot, Omid Hamid, Shailender Bhatia, Renato Martins, Keith Eaton, Shuming Chen, Theresa M Salay, Suresh Alaparthy, Joseph F Grosso, Alan J Korman, Susan M Parker, Shruti Agrawal, Stacie M Goldberg, Drew M Pardoll, Ashok Gupta, Jon M Wigginton

Author Affiliations

1: Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA.

Associated clinical trials:

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1) | NCT00729664

Articles citing this

(truncated to the top 100)

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2016) 12.86

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature (2015) 7.49

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82

Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43

Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23

Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10

Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96

Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43

Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol (2015) 4.25

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature (2012) 3.83

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol (2013) 3.77

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov (2014) 3.32

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res (2013) 3.27

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov (2013) 3.25

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature (2016) 3.18

Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest (2014) 3.06

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 2.79

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol (2013) 2.64

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell (2015) 2.60

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med (2014) 2.51

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol (2013) 2.50

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol (2014) 2.47

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41

Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. J Clin Oncol (2015) 2.40

Pseudoprogression and Immune-Related Response in Solid Tumors. J Clin Oncol (2015) 2.38

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. J Clin Oncol (2015) 2.30

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30

Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19

The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry. Cancer Prev Res (Phila) (2015) 2.17

Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity (2012) 2.16

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology (2013) 2.14

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med (2015) 2.12

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09

PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun (2016) 2.06

In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature (2014) 2.05

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res (2014) 2.00

PD-1 as a potential target in cancer therapy. Cancer Med (2013) 1.98

Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res (2013) 1.95

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun (2014) 1.95

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell (2015) 1.94

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90

CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90

Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol (2015) 1.81

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood (2015) 1.80

Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res (2014) 1.79

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol (2013) 1.79

The cancer antigenome. EMBO J (2012) 1.78

Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther (2015) 1.73

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS One (2015) 1.73

Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell (2015) 1.71

The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol (2013) 1.70

Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol (2013) 1.70

Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest (2015) 1.67

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res (2014) 1.62

Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62

The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62

Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61

Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin Cancer Res (2015) 1.61

Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol (2014) 1.61

Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med (2014) 1.59

Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther (2014) 1.58

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58

OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57

Biomarkers in early-stage non-small-cell lung cancer: current concepts and future directions. J Thorac Oncol (2014) 1.56

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell (2014) 1.55

Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.55

Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54

Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. J Am Soc Nephrol (2013) 1.54

CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat Immunol (2016) 1.54

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A (2015) 1.54

PD-1/PD-L1 inhibitors. Curr Opin Pharmacol (2015) 1.53

Articles cited by this

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81

Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med (1999) 16.91

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36

Cancer immunotherapy comes of age. Nature (2011) 12.35

PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71

CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1991) 9.94

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94

Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35

B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med (2001) 6.97

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44

PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol (2007) 6.24

Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04

Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer (2010) 5.05

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77

B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity (2004) 4.60

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J (2010) 3.99

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood (2010) 3.21

The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69

Interaction of human PD-L1 and B7-1. Mol Immunol (2008) 2.48

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34

Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy (2011) 1.74

Articles by these authors

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2003) 12.24

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71

Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10

Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72

Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08

Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64

A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res (2009) 5.99

Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87

Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36

Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77

T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 4.69

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature (2011) 4.61

Treatment of metastatic melanoma: an overview. Oncology (Williston Park) (2009) 4.58

Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56

Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51

Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol (2004) 4.43

Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31

Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28

The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 4.21

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol (2002) 4.15

Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology (2003) 4.10

An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02

Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93

Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab (2006) 3.91

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81

Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73

Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71

Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest (2008) 3.69

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42

Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch Intern Med (2010) 3.40

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40